Previous 10 | Next 10 |
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth Raises revenue guidance to $264-$268 million for full year 2019, representing 29%-31% organic growth Completes acquisition of process analytics innovator C Technologies ...
WALTHAM, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2019 financial results on Thursday, August 1, 2019. The Company will issue a press release before the market opens and will host a conference ...
Bridgebio Pharma (NASDAQ: BBIO ) initiated with Buy rating and $42 (53% upside) price target at Goldman Sachs. Initiated with Buy rating and $38 price target at Jefferies. Initiated with Outperform rating and $49 price target at BMO. Initiated with Outperform rating and $34 price target at S...
WALTHAM, Mass., July 19, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the closing of its previously announced concurrent underwritten public offerings of an aggregate of 1,587,000 shares of its common stock (the “Sharesȁ...
Repligen (NASDAQ: RGEN ) has priced its public offerings of 1,380,000 common shares of at $87.00 per share, for gross proceeds of ~$120M, and $250M 0.375% Convertible Senior Notes due 2024. More news on: Repligen Corporation, Healthcare stocks news, Read more ...
WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the pricing of concurrent underwritten public offerings of 1,380,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 ...
Gainers: JBHT +6.1% . HCR +2.9% . ARD +2.7% . HX +2.6% . TEO +1.8% . More news on: J.B. Hunt Transport Services, Inc., Hi-Crush Inc., Ardagh Group S.A., Stocks on the move, Read more ...
Repligen (NASDAQ: RGEN ) slips 3% after hours in reaction to its $100M public offering of common stock and $250M public offering of convertible senior notes due 2024. More news on: Repligen Corporation, Healthcare stocks news, Stocks on the move, Read more ...
WALTHAM, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced that it has commenced concurrent underwritten public offerings of $100,000,000 in shares of its common stock (the “Shares”) and $250,000,000 aggrega...
Investing in companies with superior growth can lead to outstanding returns over the long term. However, picking the best growth stocks is easier said than done, and a good idea without solid implementation can do more harm than good. This is especially true among growth stocks, since these ...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...